710 related articles for article (PubMed ID: 28835127)
1. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Vandamme C; Adjali O; Mingozzi F
Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
[TBL] [Abstract][Full Text] [Related]
2. Regulatory and Exhausted T Cell Responses to AAV Capsid.
Gernoux G; Wilson JM; Mueller C
Hum Gene Ther; 2017 Apr; 28(4):338-349. PubMed ID: 28323492
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
4. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
Ertl HCJ; High KA
Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943
[TBL] [Abstract][Full Text] [Related]
5. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
6. The Effect of CpG Sequences on Capsid-Specific CD8
Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
[TBL] [Abstract][Full Text] [Related]
7. Preclinical models to assess the immunogenicity of AAV vectors.
Ertl HCJ
Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
[TBL] [Abstract][Full Text] [Related]
8. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
[TBL] [Abstract][Full Text] [Related]
9. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
10. T Cell-Mediated Immune Responses to AAV and AAV Vectors.
Ertl HCJ
Front Immunol; 2021; 12():666666. PubMed ID: 33927727
[TBL] [Abstract][Full Text] [Related]
11. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
12. Genetic Engineering of AAV Capsid Gene for Gene Therapy Application.
Liu Y; Zhang X; Yang L
Curr Gene Ther; 2020; 20(5):321-332. PubMed ID: 32998676
[TBL] [Abstract][Full Text] [Related]
13. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions
Pei X; Earley LF; He Y; Chen X; Hall NE; Samulski RJ; Li C
Front Immunol; 2018; 9():844. PubMed ID: 29725339
[TBL] [Abstract][Full Text] [Related]
14. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
Rapti K; Grimm D
Front Immunol; 2021; 12():753467. PubMed ID: 34777364
[TBL] [Abstract][Full Text] [Related]
15. The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
Mays LE; Wilson JM
Mol Ther; 2011 Jan; 19(1):16-27. PubMed ID: 21119617
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
17. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
[TBL] [Abstract][Full Text] [Related]
18. CpG-depleted adeno-associated virus vectors evade immune detection.
Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
Masat E; Pavani G; Mingozzi F
Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.
Finn JD; Hui D; Downey HD; Dunn D; Pien GC; Mingozzi F; Zhou S; High KA
Mol Ther; 2010 Jan; 18(1):135-42. PubMed ID: 19904235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
